Cantor Fitzgerald Reiterates Overweight on Elevance Health, Maintains $547 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Elevance Health (NYSE:ELV) and maintained a price target of $547. This reaffirmation of the stock's rating and price target suggests continued confidence in the company's performance and potential for growth.
January 25, 2024 | 7:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald's reiteration of an Overweight rating and maintenance of a $547 price target for Elevance Health indicates a positive outlook on the company's stock, suggesting potential for growth.
The reiteration of an Overweight rating by a reputable analyst firm like Cantor Fitzgerald typically instills confidence in investors and can lead to a positive short term impact on the stock price. The maintenance of a high price target of $547 further underscores the firm's belief in the company's value and growth potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100